IQE’s £81 Million Funding Deal: MACOM Investment Ends Sale Review and Targets AI Chip-Wafer Demand

April 27, 2026
IQE’s £81 Million Funding Deal: MACOM Investment Ends Sale Review and Targets AI Chip-Wafer Demand

Cardiff, April 27, 2026, 17:03 (BST)

  • IQE announced an £81 million fundraising, with support coming from MACOM and current investors.
  • IQE’s strategic review is now wrapped up, leaving the chip-wafer maker in Cardiff to remain independent.
  • The funding still hinges on shareholder approval, plus national security clearances.

IQE plc on Monday announced that MACOM Technology Solutions Inc. is putting in £45 million, leading a broader £81 million fundraising round that wraps up a lengthy strategic review. The British supplier of semiconductor wafers had previously explored selling the whole company or certain parts. London South East

This is a significant step for IQE, as it provides the company with a way to reduce debt and unlock funds for new investment following a stretch of sluggish performance, swirling takeover rumors, and pressure on its financial position. According to IQE, the money will go toward paying down its $35 million (£27 million) revolving credit line with HSBC, redeeming outstanding convertible loan notes, and backing work involving indium phosphide and gallium nitride—key materials in fast optical and RF chips. London South East

U.S. chipmaker MACOM is set to invest £30 million in fresh IQE shares, along with £15 million in secured zero-coupon convertible loan notes. According to the company, the new shares are priced at 19.8 pence apiece—that’s a hefty 58.4% markdown from IQE’s 47.6 pence closing mid-market price on April 24. London South East

IQE shares finished Monday in London at 49.40 pence, notching a 3.8% rise ahead of the late-afternoon announcement. That gave the company a market cap near £484 million. London South East

The wider fundraising effort pulls in roughly £22.8 million from current noteholders rolling over redemption proceeds, plus an £11 million placing via accelerated bookbuild, and a retail offer that could reach £2 million. According to IQE, the placing and retail offer are slated to be available solely to existing shareholders. Investegate

Chief Executive Jutta Meier called the proposed deal “transformational for IQE” in the company’s statement, noting the funding would bolster IQE’s balance sheet and support its global presence. London South East

MACOM, for its part, announced it has plans for long-term supply deals with IQE, covering epitaxial services for several different technologies. Epitaxy involves growing extremely thin crystal layers on wafers—a crucial part of manufacturing compound semiconductors found in communications, defense, data centers, and smartphones. GlobeNewswire

“IQE is an important supplier to MACOM,” said Stephen Daly, MACOM’s President and CEO. Daly added that the deal is set to boost supply-chain resilience for MACOM, and should also give IQE some room to shore up both its balance sheet and financials. GlobeNewswire

The agreement also shakes up IQE’s board structure. Once the deal closes, MACOM gets to put forward two non-executive director candidates for IQE’s board. IQE, for its part, noted that Lombard Odier will lose its right to name a second non-executive director after its current loan notes are redeemed. London South East

IQE has wrapped up talks with multiple suitors after exploring potential deals during its review. The group confirmed it’s dropped all discussions with third-party bidders for the entire company. It’s also out of the offer period set by the UK Takeover Code. London South East

Management is seeing a stronger commercial environment. IQE reported first-quarter trading met its budget, citing demand for photonics products linked to AI computing and data-center projects, along with VCSEL and wireless products for smartphones. The company is forecasting revenue growth north of 20% for 2026 compared with the previous year. Investegate

But there’s no guarantee the deal closes. The fundraising still requires shareholder signoff at the general meeting set for May 15, plus regulatory signoff under both the UK National Security and Investment Act and Italy’s foreign-direct-investment rules. IQE has flagged that if shareholders reject the proposals, the fundraising is dead—and the company would be pushed to seek emergency cash to cover its near-term liquidity. Investegate

Stock Market Today

  • How Many British American Tobacco Shares to Earn £6,581 Passive Income Annually?
    May 19, 2026, 5:55 AM EDT. British American Tobacco (LSE: BATS) is a FTSE 100 heavyweight known for its high, reliable dividend yield, currently forecasted around 5.4%-5.8% over the next few years. A discounted cash flow (DCF) analysis, applying an 8.7% discount rate, suggests the stock is 31% undervalued at £49.24, with a fair value near £71.36. Buying 406 shares with £20,000 could generate approximately £15,671 in dividends over 10 years and £93,470 over 30 years, assuming dividend reinvestment and compounding. After 30 years, the holding's annual dividend income could reach £6,581, despite some risks from regulatory pressures and shifting tobacco product sales. The company forecasts profit growth of 4%-8% through 2026, supporting sustained dividend payouts.